• Home
• Our Motivation
  • Patient Stories
    • Annabelle
    • Isabel
    • Matty
    • Miller
    • Sarah
  • Diseases & Conditions
    • Achondroplasia
    • PKU
    • CLN2 Disease
    • MPS VI
    • MPS IVA
    • MPS I
  • Patient & Community Support
    • Trees of Life
    • RARE Scholars
    • In the Hemophilia Community
    • Patient Advocacy
    • BioMarin RareConnections™
    • Grants & Donations
  • Resource Library
    • Patient Organizations
    • Professional Organizations
• Our Science
  • Our Approach
    • Technical Expertise
    • Indication Expansion
    • Franchise Building
  • Our Scientists
  • Our Publications
  • Science Spotlight
    • Advancing our understanding of gene therapy research, one publication at a time
    • Zeroing in on Therapeutic Drug Targets
    • Meet the Scientist: Christian Vettermann, Ph.D.
    • BioMarin’s Center of Technology empowers scientists with technology, resources, and collaboration
  • Funding & Support
    • Independent Medical Education
    • Independent Research
    • Publication Data Request
• Our Treatments
  • Our Products
    • VOXZOGO® (vosoritide)
    • PALYNZIQ® (pegvaliase-pqpz) Injection for PKU
    • BRINEURA® (cerliponase alfa) for CLN2 Disease
    • VIMIZIM® (elosulfase alfa) for Morquio A Syndrome (MPS IVA)
    • KUVAN® (sapropterin dihydrochloride) for PKU
    • NAGLAZYME® (galsulfase) for MPS VI
    • ALDURAZYME® (laronidase) for MPS I
  • Our Pipeline
  • Compassionate Use Policy
• Our Company
  • About Us
    • Our History
    • Manufacturing Excellence
    • Message from Chairman and CEO
    • Diversity, Equity & Inclusion
    • Global Compliance & Ethics
  • Corporate Social Responsibility
  • Leadership Team
    • Jean-Jacques Bienaimé
    • Henry J. Fuchs, M.D.
    • Jeff Ajer
    • G. Eric Davis
    • C. Greg Guyer, Ph.D.
    • Brian R. Mueller
    • Philip Lo Scalzo
    • Amy Wireman
    • Brinda Balakrishnan, M.D., Ph.D.
  • Board of Directors
  • Funding & Support
    • Independent Medical Education
    • Independent and Collaborative Research
    • Grants & Donations
• Investors & Media
  • Press Releases
  • Events & Presentations
  • Corporate Governance
    • Committee Composition
    • Contact the Board
  • Financial Information
    • SEC Filings
    • Annual Reports
    • Quarterly Results
    • Key Ratios
    • Financial Statements
  • Analyst Coverage
  • Stock Information
    • Historic Stock Lookup
  • Investor FAQs
  • Contact Us
  • Email Alerts
• Clinical Trials
  • Achondroplasia
    • VOXZOGO® (vosoritide) Injection for Achondroplasia
  • Hemophilia A
  • Achondroplasia
  • PKU
    • KUVAN® (sapropterin dihydrochloride) Tablets and Powder for Oral Solution
    • PALYNZIQ® (pegvaliase-pqpz) Injection
  • MPS IVA
  • MPS VI
  • CLN2 Disease
• Contact Us
  • Locations
  • Global Medical Information
  • Report Adverse Event
  • Report a Product Complaint
• Careers
• Blog
  • Advancing our understanding of gene therapy research, one publication at a time
  • Zeroing in on Therapeutic Drug Targets
  • BioMarin’s Center of Technology empowers scientists with technology, resources, and collaboration
  • Meet the Scientist: Christian Vettermann, Ph.D.
• Privacy Policy
• Terms of Use
• Supplier Information
• Glossary
• UK Modern Slavery Act and Supply Chain Transparency Statement